Dose‐ranging antiemetic evaluation of the serotonin antagonist rg 12915 in patients receiving anticancer chemotherapy
Amyotrophic Lateral Sclerosis
Nerve Growth Factors
RG 12915 can be administered safely at the dose levels explored. Single intravenous doses of RG 12915 prevented or lessened emesis caused by chemotherapy, including cisplatin given at doses of greater than or equal to 100 mg/m2. RG 12915 warrants further testing. Of the doses tested, the 2.0 mg/kg dose is the most appropriate for further exploration.